• News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Rights Issue / Företrädesemission 2022
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Share Information
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Career
  • Contact
logo
  • News
    • News
    • Upcoming Events
    • Subscribe
  • Our Company
    • Our Story
    • Our Vision
    • CEO Statement
    • Board of Directors
    • Alzinova Team
    • Advisers & Collaborators
  • Patients & Families
    • Alzheimer's Patients
    • Impact on Society
    • The Unmet Medical Need
  • R & D
    • Alzheimer's Disease
    • Our Programs
    • Specific Targeting of Toxic Aβ Oligomers
    • The AβCC Peptide™ Technology
  • Investors
    • Overview
    • Rights Issue / Företrädesemission 2022
    • Press Releases
      • English
      • Swedish
      • Subscribe
    • Presentations
    • Company Presesentation
    • The Share
      • Share Information
      • Largest Shareholders
      • Share Capital Development
      • Rights Issues / Företrädesemissioner
      • Previous Share Issuances
      • Analyst Coverage
    • Financial Reports
      • English
      • Swedish
    • Financial Calendar
    • Corporate governance
      • General Meetings
      • Nomination Committee / Valberedning
      • Auditor
      • Articles of Association
      • Board of Directors
      • Management
    • Certified Adviser
    • IR Contact
  • Career
  • Contact
Home / Investors / The Share
  • Overview
  • Rights Issue / Företrädesemission 2022
  • Press Releases
    • English
    • Swedish
    • Subscribe
  • Presentations
  • Company Presentation
  • The Share
    • Share Information
    • Largest Shareholders
    • Share Capital Development
    • Rights Issues / Företrädesemissioner
    • Analyst Coverage
  • Financial Reports
    • English
    • Swedish
  • Financial Calendar
  • Corporate Governance
    • General Meetings
    • Nomination Committee / Valberedning
    • Previous Nomination Committees
    • Auditor
    • Articles of Association
    • Board of Directors
    • Management
  • Certified Adviser
  • IR Contact

Share Information

The Alzinova share is traded on Nasdaq First North Growth Market. The company has a registered share capital of 8,526,205.942 SEK, divided on 32,419,034 shares. The quota value is 0.263 SEK/share.

Name: Alzinova AB
Ticker: ALZ
ISIN code: SE0007413455
LEI-code: 549300K3IMVT20EK2S13

Share price and trading can be followed on Nasdaq First North Growth Market

The Company has an agreement with Mangold Fondkommission according to which Mangold Fondkommission acts as a liquidity provider in the Company’s share that is traded on Nasdaq First North Growth Market. The purpose of the liquidity provider, is to improve the liquidity of the Alzinova share and reduce the difference between the buying and selling price.

Shares are registered by Euroclear Sweden AB

  • News
  • Our Company
  • Patients & Families
  • R & D
  • Investors
  • Contact

Alzinova AB. Pepparedsleden 1, SE-431 83, Mölndal, Sweden
+46 (0) 708 467 975   info@alzinova.com

Follow us on

follow us on linkedin